Evidence map›Paper›PMID 34349986›Full record

ReviewTherapeutic advances in infectious disease

COVID-19: a review of current knowledge regarding exposure, quarantine, isolation and other preventive measures.

Robert Rosolanka, Andres F Henao-Martinez, Larissa Pisney, Carlos Franco-Paredes, Martin Krsak

Abstract readReview
In one paragraph

Review in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. COVID-19 and Alzheimer's Disease: A Literature Review.Medicina (Kaunas, Lithuania) · 2021
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Robert RosolankaDepartment of Infectology and Travel Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollárova 2, Martin, 036 01, Slovakia.ORCID https://orcid.org/0000-0003-0429-6833
Andres F Henao-MartinezDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.ORCID https://orcid.org/0000-0001-7363-8652
Larissa PisneyDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Carlos Franco-ParedesDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.ORCID https://orcid.org/0000-0001-8757-643X
Martin KrsakDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deeper understanding of the spread, morbidity, fatality, and development of immune response associated with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is necessary in order to establish an appropriate epidemiological and clinical response. Exposure control represents a key part of the combat against COVID-19, as the effectiveness of current therapeutic options remains partial. Since the preventive measures have not been sufficiently able to slow down this pandemic, in this article we explore some of the pertinent knowledge gaps, while overall looking to effective vaccination strategies as a way out. Early on, such strategies may need to rely on counting the convalescents as protected in order to speed up the immunization of the whole population.

Indexed as

coronavirus disease 2019epidemiologyexposureinfectivityisolationquarantinesevere acute respiratory syndrome coronavirus 2

Identifiers

PMID34349986
PMCPMC8287266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.